Wang T - Search Results

1

[Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer.].

Wang T, Sun J, Gao W, Shen H, Li X, Yin Y, Shu Y, Guo R. Wang T, et al. Zhongguo Fei Ai Za Zhi. 2009 Dec 20;12(12):1287-90. doi: 10.3779/j.issn.1009-3419.2009.12.12. Zhongguo Fei Ai Za Zhi. 2009. PMID: 20723385 Free article. Chinese.

2

Paeoniflorin suppress NF-kappaB activation through modulation of I kappaB alpha and enhances 5-fluorouracil-induced apoptosis in human gastric carcinoma cells.

Wu H, Li W, Wang T, Shu Y, Liu P. Wu H, et al. Among authors: wang t. Biomed Pharmacother. 2008 Nov;62(9):659-66. doi: 10.1016/j.biopha.2008.08.002. Epub 2008 Aug 31. Biomed Pharmacother. 2008. PMID: 18809274

3

Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.

Guo R, Wang T, Shen H, Ge HM, Sun J, Huang ZH, Shu YQ. Guo R, et al. Among authors: wang t. Biomed Pharmacother. 2010 Apr;64(4):249-53. doi: 10.1016/j.biopha.2009.06.007. Epub 2009 Oct 22. Biomed Pharmacother. 2010. PMID: 19931998

4

[Effects of survivin in tamoxifen-induced inhibition of proliferation and enhancement of apoptosis in hepatoma Hep22 cells].

Guo RH, Wang TS, Liu LK. Guo RH, et al. Zhonghua Zhong Liu Za Zhi. 2009 Oct;31(10):752-3. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 20021827 Chinese. No abstract available.

5

miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.

Zhu W, Shan X, Wang T, Shu Y, Liu P. Zhu W, et al. Among authors: wang t. Int J Cancer. 2010 Dec 1;127(11):2520-9. doi: 10.1002/ijc.25260. Int J Cancer. 2010. PMID: 20162574

6

[Down-regulation of mTOR activity and survivin expression during tamoxifen-induced apoptosis in hepatoblastoma cells].

Guo RH, Wang TS, Chen XF, Huang ZH, Shu YQ. Guo RH, et al. Zhonghua Zhong Liu Za Zhi. 2010 Dec;32(12):903-6. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21223797 Chinese.

7

miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.

Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B, Shu Y, Liu P. Zhu W, et al. Among authors: wang j, wang t. Med Oncol. 2012 Mar;29(1):384-91. doi: 10.1007/s12032-010-9797-4. Epub 2011 Jan 22. Med Oncol. 2012. PMID: 21258880

8

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.

Guo R, Chen X, Wang T, Zhang Z, Sun J, Shu Y. Guo R, et al. Among authors: wang t. BMC Cancer. 2011 Mar 2;11:90. doi: 10.1186/1471-2407-11-90. BMC Cancer. 2011. PMID: 21366910 Free PMC article.

9

Phase II study of weekly irinotecan plus cisplatin in patients with previously untreated extensive-stage extrapulmonary small cell carcinoma.

Jin S, Wang T, Chen X, Xu B, Sun J, Guo R, Shu Y. Jin S, et al. Among authors: wang t. Onkologie. 2011;34(7):378-81. doi: 10.1159/000329609. Epub 2011 Jun 24. Onkologie. 2011. PMID: 21734424 Clinical Trial.

10

miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P. Zhu W, et al. Among authors: wang j, wang t. Cancer Chemother Pharmacol. 2012 Mar;69(3):723-31. doi: 10.1007/s00280-011-1752-3. Epub 2011 Oct 13. Cancer Chemother Pharmacol. 2012. PMID: 21993663

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52,460 results

Search Page

Filters